Stock Market Drops After Fed Rate Cut, Merck Enters Obesity Drug Race

  • 📰 CNBC
  • ⏱ Reading Time:
  • 75 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 50%
  • Publisher: 72%

BUSINESS Nouvelles

FED,RATE CUT,STOCK MARKET

The Federal Reserve cut interest rates by 25 basis points but the market reacted negatively. Merck made a $2 billion deal for an experimental obesity drug.

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Rate cut reaction: The stock market reversed its gains and dropped after the Federal Reserve on Wednesday afternoon cut interest rates by 25 basis points to the target range of 4.25% to 4.50. The vote was not unanimous. There was one dissenting vote by Cleveland Fed President Beth Hammack, who was in favor of no cuts.

The December meeting included an update to the monetary policymakers' Summary of Economic Projections — including the excessively analyzed 'dot plots,' which provide a glimpse into where Fed members expect rates to be over the next three years and the longer term. The dot plots showed a median forecast of 50 basis points of easing, or two 25-basis-point rate cuts, in 2025. This suggests the Fed anticipates fewer rate cuts next year than what it expected in September. As a result, the 2-year Treasury yield surged higher. So far, it appears to be the 'hawkish cut' that we expected. Fed Chairman Jerome Powell has previously indicated that central bankers are in no rush to cut rates, and every decision made will be data-dependent. Powell is talking to reporters at his post-meeting press conference. We are monitoring his comments and will update this story as needed. Obesity race: The obesity arms race continues to heat up. This time it was Merck throwing its hat in the ring in a deal with a Chinese drugmaker that could be valued as much as $2 billion. The lead asset acquired in the deal is an experimental oral GLP-1. The Chinese company's drug is in the preclinical stage and hasn't entered human trials. Wall Street has been waiting for Merck to get into this market, but we think it's way too premature to say this is a potential threat to the dominance of Novo Nordisk and Club name Eli Lilly in this class of drugs, which are used primarily to treat obesity and diabetes

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 12. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Meme Coin Market Cap Surpasses U.S. Quantum Stock MarketCryptocurrency analyst Charles Edwards highlights the disparity between the market capitalization of meme coins like Dogecoin and the entire U.S. quantum stock market. Edwards questions the sustainability of this trend, suggesting it may not last long.
La source: Utoday_en - 🏆 295. / 63 Lire la suite »

Market Volatility: Is the US Stock Market in a Bubble?The article discusses the current state of the US stock market, highlighting the record highs of the Nasdaq, the Dow's recent losing streak, and the flat performance of the S&P 500. It analyzes the market's exuberance, potential for a pullback, and the attractiveness of traditional S&P 500 investments.
La source: NBCNewYork - 🏆 270. / 63 Lire la suite »

The ripple effect of 5% treasury yields: How higher rates shape stock market dynamicsRecently – we have been discussing the impact of higher rates on global stock markets - here is a quick analysis of what a 5% - 10-year Treasury yield would have on stocks.
La source: FXStreetNews - 🏆 14. / 72 Lire la suite »